COEP News and Press, Coeptis Therapeutics Inc From 04/25/25

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Coeptis Therapeutics Holdings, Inc. (NASDAQ: COEP) and Z Squared Inc. is fair to Coeptis shareholders. Halper Sadeh encourages Coeptis shareholders to click here to learn more about their legal rights an...

2025-04-25 09:08:04 ET More on Coeptis Therapeutics Financial information for Coeptis Therapeutics Holdings, Inc. Read the full article on Seeking Alpha For further details see: Coeptis Therapeutics, Z Squared announce merger agreement

WEXFORD, Pa., April 25, 2025 (GLOBE NEWSWIRE) -- Coeptis Therapeutics Holdings, Inc. (Nasdaq; COEP) (“Coeptis” or the “Company”), a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune and infectious di...

2025-04-23 02:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

WEXFORD, Pa., April 17, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions, is excited to announce the establishment of a new co-working technology hub in India in partnership with...

2025-04-06 18:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Vivos Inc (RDGL) is expected to report for quarter end 2024-12-31 Nickel Creek Platinum Corp (NCPCF) is expected to report for quarter end 2024-12-31 ViewBix Inc (VBIXD) is expected to report for quarter end 2024-12-31 Forte Biosciences Inc. (FBRX) is expected to report $-4.55 for Q4 ...

• COEP forms GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified natural killer (NK) cells into first-in-human studies for broad range of cancers and other therapeutic modalities. WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP...

WEXFORD, Pa., March 07, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "COEPTIS"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced its strategic partnership with COEPTIS’ NexGenAI Affiliates Network “NexGen...

WEXFORD, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- COEPTIS, Inc. (Nasdaq: COEP) ("the Company" or "Coeptis"), a pioneering technology firm at the forefront of innovative biotechnology solutions today announced an exciting strategic partnership with COEPTIS’ NexGenAI Affiliates Network and Ark...